Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$131.82 USD
-0.48 (-0.36%)
Updated May 10, 2024 04:00 PM ET
After-Market: $131.94 +0.12 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Sarepta Therapeutics, Inc. [SRPT]
Reports for Purchase
Showing records 641 - 659 ( 659 total )
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of September 30.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Eteplirsen 48-Week Data Preview: Longer-Term Administration Key to Eteplirsen''s Clinical Benefit - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
September 2012 Potential Catalysts & Milestones - Monthly Update
Provider: WEDBUSH SECURITIES INC.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Eteplirsen Reportedly Improves Quality of Life of a DMD Patient
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Eteplirsen Reportedly Improves Quality of Life of a DMD Patient
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2:12 Update - Eteplirsen Program Remains Attractive - Ebola Stop Work Order Non-Event - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Reports FY 2Q12 Earnings; Several Upcoming Catalysts in 2H12
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Reports FY 2Q12 Earnings; Several Upcoming Catalysts in 2H12
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of July 29
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Increasing Price Target to $26 - Eteplirsen Shows Statistically Significant Clinical Benefit in 6-Minute Walk
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Unprecedented Benefit in DMD Patients Reported By Use of Eteplirsen in Study 202
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Unprecedented Benefit in DMD Patients Reported By Use of Eteplirsen in Study 202
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
100% Survival Reported in a Non-human Primate Study of AVI-7288 for Marburg Virus
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
100% Survival Reported in a Non-human Primate Study of AVI-7288 for Marburg Virus
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M